Therapy
Heel and Toe supports hundreds of children each year to make life-changing progress
Chroma's sessions delivering increases in independence and participation at Voyage Care home
Adoption of Rebound Therapy at St Andrew's Healthcare delivering physical and mental health benefits
NR Times reports on the much-anticipated trial of ALS treatment AMX0035, in an interview with Machelle Manuel, head of global medical affairs at its creator Amylyx.
Recently approved for treating ALS in the US, AMX0035 is now the subject of a major phase 3 clinical trial taking place across the US and Europe. ALS is a relentlessly progressive and fatal neurodegenerative disorder that up until recent decades was thought to be impossible to treat. While the cause of the condition is still uncertain, a new wave of treatments is coming to the fore. Sign up to NR Times to read our interview in full.
Physiotherapist Harpreet Kaur provides a useful summary of physical therapy interventions for hemiplegia.
Hemiplegia is a condition that involves paralysis or weakness of one side of the body due to damage to the brain or spinal cord. Rehabilitation is an integral part of treatment for hemiplegia. The focus is to help the affected individual regain as much movement and independence as possible through various therapeutic interventions. Rehabilitation for hemiplegia is typically tailored to the individual's specific needs and goals. It may involve a combination of different therapies to achieve the best possible outcome. The following are the common approaches used in hemiplegia rehabilitation:
How the team is making speech and language support diverse and accessible for all
NR Times meets Coya Therapeutics’ founder and CEO Howard Berman as he closes in on his mission to halt ALS / motor neurone disease and other neurodegenerative conditions.
“Even if we see results that are half as good what we’ve already seen, this is going to change the way ALS is treated,” says Howard Berman, founder and CEO of Coya Therapeutics. The results he points to, which caused much excitement in the neuroscience research community last month, showed four people with ALS treated with Coya’s immune modulating therapy experienced a significant slowing of disease progression. ALS is the most common form of motor neurone disease (MND), while, in the US, it is also the umbrella term for MND. Coya's therapy has emerged from the Nasdaq-listed firm’s pursuit of treatments based on the enhancement of the function of regulatory t cells (Tregs) in the immune system. Read on to find out how Coya aims to build on its early promising results to change the outlook for people with ALS / motor neurone disease and wider neurodegenerative diseases. Also, we hear how the neuro-rehab community is helping to drive new treatment possibilities and why Tregs are becoming so important to our understanding of brain conditions.
How The Coaching and Therapy People are delivering personalised solutions for people with neurological conditions
Neuro Rehab Times meets dramatherapist Katy Weston, who uses drama to help traumatic brain injury survivors.
By Dr Alyson Norman, associate professor at the University of Plymouth and deputy chair of Anchor Point. According to Headway UK, there were 356,699 admissions to hospital due to an acquired brain injury in 2019-20201. While some individuals do make a full recovery, for many a brain injury marks the beginning of a life-long struggle. [...]
